Chimeric antigen receptor (CAR) T cell therapy has opened new possibilities for patients with refractory autoimmune diseases such as systemic sclerosis, but personalized manufacturing and treatment-related toxicities limit its broader use. In this preview, we discuss the first clinical application of an off-the-shelf, iPSC-derived CAR-NK cell product in systemic sclerosis as reported by Wang et al. in this issue of Cell.